Stock Track | Ocular Therapeutix Plunges 6.45% in Pre-Market After Q1 Earnings Miss Estimates

Stock Track05-05

Ocular Therapeutix's stock tumbled 6.45% in pre-market trading on Tuesday following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on both earnings and revenue.

The biopharmaceutical company reported a net loss of $0.40 per share, wider than the FactSet consensus estimate of a $0.31 loss. Revenue for the quarter reached $10.8 million, missing the $12.6 million estimate. The company's net loss widened to $88.6 million from $64.1 million a year earlier, driven by a significant increase in research and development expenses to $66.2 million from $42.9 million.

Despite the disappointing financial results, Ocular Therapeutix maintained a strong cash position of $666.7 million as of March 31, 2026, which the company expects will fund operations into 2028. The company also provided updates on its clinical trials, including progress with its AXPAXLI investigational product for wet age-related macular degeneration.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122112768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-05 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122112768","market":"nz","top_or_hot":-1,"title":"Stock Track | Ocular Therapeutix Plunges 6.45% in Pre-Market After Q1 Earnings Miss Estimates","media":"Stock Track","content":"<p>Ocular Therapeutix's stock tumbled 6.45% in pre-market trading on Tuesday following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on both earnings and revenue.</p><p>The biopharmaceutical company reported a net loss of $0.40 per share, wider than the FactSet consensus estimate of a $0.31 loss. Revenue for the quarter reached $10.8 million, missing the $12.6 million estimate. The company's net loss widened to $88.6 million from $64.1 million a year earlier, driven by a significant increase in research and development expenses to $66.2 million from $42.9 million.</p><p>Despite the disappointing financial results, Ocular Therapeutix maintained a strong cash position of $666.7 million as of March 31, 2026, which the company expects will fund operations into 2028. The company also provided updates on its clinical trials, including progress with its AXPAXLI investigational product for wet age-related macular degeneration.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ocular Therapeutix Plunges 6.45% in Pre-Market After Q1 Earnings Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ocular Therapeutix Plunges 6.45% in Pre-Market After Q1 Earnings Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-05 21:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ocular Therapeutix's stock tumbled 6.45% in pre-market trading on Tuesday following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on both earnings and revenue.</p><p>The biopharmaceutical company reported a net loss of $0.40 per share, wider than the FactSet consensus estimate of a $0.31 loss. Revenue for the quarter reached $10.8 million, missing the $12.6 million estimate. The company's net loss widened to $88.6 million from $64.1 million a year earlier, driven by a significant increase in research and development expenses to $66.2 million from $42.9 million.</p><p>Despite the disappointing financial results, Ocular Therapeutix maintained a strong cash position of $666.7 million as of March 31, 2026, which the company expects will fund operations into 2028. The company also provided updates on its clinical trials, including progress with its AXPAXLI investigational product for wet age-related macular degeneration.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCUL","symbol_name":"Ocular Therapeutix","start_time":0,"source_url":"","article_id":"1122112768","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122112768","pubTimestamp":1777987625,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ocular Therapeutix's stock tumbled 6.45% in pre-market trading on Tuesday following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on both earnings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCUL":"Ocular Therapeutix"},"translate_title":"个股追踪|Q1财报不及预期Ocular Therapeutix盘前暴跌6.45%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUL":1},"content_text":"Ocular Therapeutix's stock tumbled 6.45% in pre-market trading on Tuesday following the release of its first-quarter 2026 financial results, which fell short of analyst expectations on both earnings and revenue.The biopharmaceutical company reported a net loss of $0.40 per share, wider than the FactSet consensus estimate of a $0.31 loss. Revenue for the quarter reached $10.8 million, missing the $12.6 million estimate. The company's net loss widened to $88.6 million from $64.1 million a year earlier, driven by a significant increase in research and development expenses to $66.2 million from $42.9 million.Despite the disappointing financial results, Ocular Therapeutix maintained a strong cash position of $666.7 million as of March 31, 2026, which the company expects will fund operations into 2028. The company also provided updates on its clinical trials, including progress with its AXPAXLI investigational product for wet age-related macular degeneration.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122112768","isCrawlerRequest":true}